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Background: Acute kidney injury (AKI) is a public health problem that discounted quality-adjusted life years for both cohorts were 1049 and
affects millions of hospitalized patients worldwide. In Argentina, ev-
idence suggests that its incidence has risen in recent years. When
severe, AKI may require a renal replacement therapy (RRT) where
continuous RRT (CRRT) and intermittent RRT (IRRT) are plausible op-
tions for patients in the intensive care unit. Objective: To evaluate the
cost utility of CRRT versus IRRT for the National Institute of Social
Services for Retirees and Pensioners, the largest social security health
insurance for elders in Argentina. Methods: This was a model-based
cost-utility analysis. Long-term costs and health outcomes were esti-
mated for a hypothetical cohort with a Markov model. Parameters used
wereobtained frompublishedliteratureandvalidatedwith localexperts.
Local costs were estimated and expressed in $AR of 2016. Several
sensitivity analyses were run to analyze the impact of uncertainty on
results. Results: Continuous RRT dominated IRRT by cumulating over
the model more quality-adjusted life years and less costs. TotalConflict of interest: Baxter Inc. did not participate in any phase of
Mr Garay’s affiliation during the entire research was IECS, but in Mar
* Address correspondence to: Osvaldo Ulises Garay, MSc, IECS Arg
Email: osvaldoulisesgaray@gmail.com
2212-1099/$36.00 - see front matter © 2019 ISPOR–The professional so
Elsevier Inc.
https://doi.org/10.1016/j.vhri.2019.03.0081034, respectively, and total costs were $95362 and $103871. Cost-
effectiveness (CE) results reflect these differences in favor of CRRT
with a deterministic cost-saving incremental CE ratio and a probability
of CRRT being CE of 65.4%, considering a CE threshold of 1 gross do-
mestic product per capita. Conclusions: Continuous RRT for patients
with AKI eligible for CRRT or IRRT would probably be a cost-effective
intervention for the National Institute of Social Services for Retirees
and Pensioners’ view. Nevertheless, there is considerable uncertainty
around results, mainly due to the lack of adequate controlled studies
and local data on the prognosis of these patients in Argentina.
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economic evaluation
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Acute kidney injury (AKI) is a public health problem that affects
millions of hospitalized patients worldwide. It is associated with
increased mortality, longer hospital stays, high financial costs,
and increased risk of developing chronic diseases.1e3 Owing to its
high incidence, it represents one of the most frequent reasons for
consultation in nephrology departments.4 Estimations of preva-
lent cases range from 2000 to 15 000 patients per million people
per year.5,6 The multinational AKI-EPI study, which included 1032
intensive care unit (ICU) patients from 97 centers in 33 countries,
found that 57.3% of patients suffered AKI during hospitalization,
with sepsis and hypovolemia as the most common etiologies.7Acute kidney injury is considered an independent risk factor
for mortality.8,9 Its unadjusted mortality is estimated to be 23.9%
in adults and 13.8% in children worldwide, increasing with the
severity of AKI.9,10 Aging is strongly associated with an increased
risk and incidence of AKI.11 Even if patients survive an episode of
AKI, few recover their renal function ad integrum. Many patients
with AKI, in particular the elderly and those bearing preexisting
chronic kidney disease (CKD), will progress to CKD or worsen it.12
The risk of developing CKD is 28 times higher in those patients
with AKI requiring renal replacement therapy (RRT) versus those
without AKI,13 and 2.7% requiring RRT will evolve to terminal CKD
in the following 3 years, with dialysis dependence (DD).14 Acute
kidney injury also leads to longer hospital stays, greater risk ofthe study, and all results are responsibility of the signing authors.
ch 2018 the author changed affiliation to Roche Diagnostics.
entina, Buenos Aires 1414, Argentina.
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Figure 1 – Markov Model. Adapted from Ethgen et al.25 AKI
indicates acute kidney injury; ICU, intensive care unit;
CRRT, continuous renal replacement therapy; IRRT,
intermittent renal replacement therapy.
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disease.15
In the AKI-EPI study, from all patients with AKI, RRT was
needed in 23.5% of the cases.7 Renal replacement therapy can be
provided with an intermittent mode (IRRT) or continuous mode
(CRRT). Both techniques are not mutually exclusive but comple-
mentary16; however, in some specific situations, international
guidelines recommend the preferential use of CRRT, including
conditions such as hemodynamic instability, cerebral edema,
acute brain injury with increased intracranial pressure, and
persistent metabolic acidosis.15 Evidence from randomized
controlled trials (RCTs) and meta-analyses have shown no dif-
ferences in mortality between both modalities,17e19 but other ev-
idence suggest that CRRT is associated with lower rates of
dialysis-dependent CKD compared with IRRT.13,20
In Argentina, a local prospective study done in 9 ICUs found a
prevalence of AKI in ICU of 52% to 69% according to different sets
of definition criteria, with the risk of mortality being 41% to 45%.21
Most of these patients in Argentina receive medical attention
through the National Institute of Social Services for Retirees and
Pensioners (PAMI), the largest social security health insurance for
elders, whose beneficiaries are mainly retired people, pensioners
over 70 years old, and ex-combatants of the Malvinas war.
Because of technology availability and coverage policies, CRRT is
not commonly a therapy option for PAMI’s patients requiring
RRT.22 Because of its potential reduction in dialysis dependency
and considering CRRT was shown to be cost-effective in different
countries,23e25 it is a relevant research question if CRRT would be
a cost-effective option compared with IRRT for PAMI’s views. This
study objective, then, is to evaluate the cost utility of CRRT versus
IRRT for PAMI.Methods
General Overview
This is a cost utility analysisdmany times referred to as cost-
effectiveness (CE) analysis in the literaturedthat compares the
costs and health-related quality of life of 2 RRTs for acute patients
in the ICU setting, CRRT and IRRT, from the perspective of PAMI, a
social health insurance with near 4 million enrollees, mainly se-
nior citizens.26 Costs and health benefits were estimated with a
state transitionmodel and in turnwere discounted using a 5% rate
based on theMethodological Guidelines for Economic Assessment
Studies of Mercosur.27 The population is a hypothetical cohort of
1000 acute patients who are eligible to receive either therapy. This
study followed the Consolidated Health Economic Evaluation
Reporting Standards recommendations for reporting economic
health assessments.28 The CE threshold was defined to be 1 gross
domestic product (GDP) per capita, estimated for Argentina as
$13467 by The World Bank for 2015.29State Transition Model and Outcomes Estimations
A state transition or Markov model, adapted from Ethgen et al,25
was used to estimate long-term costs and health outcomes (see
Fig. 1). Patients enter the model with AKI at ICU where they
receive 1 of 2 types of renal replacement therapies analyzed
(IRRT or CRRT). To capture relevant differences between treat-
ment options, Markov cycles were defined on a daily basis. The
main model outcome is chronic DD after discharge from hospital.
Patients can die from any cause anytime. The base-case time
horizon was defined in 10 years, but longer time horizons were
explored using scenario analyses. Incremental cost-effectiveness
ratios (ICERs) of CRRT compared with IRRT were calculated as
Dcosts /DQALYs, that is, the ratio between the difference incumulative total costs and quality-adjusted life years (QALYs)
between strategies. Additionally, net monetary benefit (NMB),
estimated as DQALYs * l e Dcosts (cumulative difference of
QALYs times the CE threshold minus the total cost difference)
and probabilities of CRRT being cost-effective (P[CE]) were
calculated.Model Parameters Estimation
Required parameters to run the model are listed in Table 1. We
conducted a literature review in PubMed, Cochrane Library,
EMBASE, LILACS, the International Society for Pharmacoeco-
nomics and Outcomes Research scientific presentations database,
and Google Scholar to identify useful information to estimate
them. The search strategies, which are available in the Appendix
in Supplemental Materials found at https://doi.org/10.1016/j.
vhri.2019.03.008, were adapted to obtain local data related to the
epidemiology, resource usage, efficacy, and quality of life of RRT in
elderly patients with acute renal failure. Searches were performed
from inception until January 12, 2017, without language re-
strictions. A search for ongoing clinical trials was also conducted
on ClinicalTrials.gov and the World Health Organization Inter-
national Clinical Trials Registry Platform. Additionally, a local
panel of 6 nephrology experts estimated missing parameters and
validated the estimations for Argentina. Consensus was reached
with a Delphi-like panel method.Epidemiological and Clinical Parameters
Epidemiological and clinical parameters needed were associated
with the population characteristics, clinical outcomes related to
ICU stay, survival after ICU discharge, risk of chronic DD, and
quality of life (see Table 1). We defined the age at the time of RRT
in 65 years because the studies we used to characterize survival
rates reported the same.18,30,31 The average length of stay for this
population in ICU was established by our local experts panel in
14.2 (5.00-27.2) days, indistinctly for both types of RRT. This is in
line with previous studies.13,32 To characterize the duration of RRT
in the ICU, we used the reference for CRRT reported by Uchino
2005,33 which corresponds to an observational study that included
1218 patients from 23 countries. Aiming to keep a conservative
strategy, we decided to use the same value of 6 days (95% CI: 3-15)
for both RRTs. The switch from CRRT to IRRT refers to the per-
centage of individuals with CRRT as initial therapy in the ICU who
Table 1 – Parameter used in the base-case model, variability range, probability distributions, and reference. PAMI,
Argentina, 2016.
Parameters Base case Variability rangey Probability distribution‡ Source
ICU stay
ICU stay with RRT (days) 14.20 (5.00-27.20) Gamma (6.29; 2.26) Delphi panel
RRT duration (days)* 6.00 (3.00-15.00) Gamma (3.84; 1.56) Uchino 200732
Switch from CRRT to IRRT (%) 37.33 (15.00-47.50) Beta (12.33; 20.70) Delphi panel
Switch from IRRT to CRRT (%) 35.00 (12.50-42.50) Beta (13.24; 24.60) Delphi panel
Survival (%)
Discharged alive from ICU* 45.33 (29.83-55.67) Beta (25.42; 30.65) Delphi panel
Alive at 60 days of treatment* 33.50 (24.00-42.00) Beta (35.06 ; 69.60) Delphi panel
Alive at 180 days of treatment* 30.00 (20.42-40.75) Beta (23.12; 53.94) Delphi panel
Dialysis dependence at 90 days from RRT
In IRRT (%) 20.80 (20.31-21.25) Beta (5961.58; 22 699.86) Wald 201413
Relative risk (CRRT/IRRT) 0.68 (0.38-1.22) Log-normal (0,33; 0,30) Wald 201413 y Schneider 201318
Health utilities
ICU stay* 0.34 (0.38 to 0.18) Normal (0.34; 0.05) Delphi panel
Dialysis independence (DI)* 0.81 (0.65-0.90) Normal (0.81; 0.06) Delphi panel
Dialysis dependence (DD)* 0.63 (0.46-0.77) Normal (0.63; 0.08) Delphi panel
Cost per day ($AR)x
CRRT 7779.13 (6210.29-10 985.18) Log-normal (8.95; 0.15) Delphi panel. PAMI41,42
IRRT 1952.92 (1562.34-4300.00) Log-normal (7.51; 0.41) PAMI41,42
DI 3.42 (2.74-4.11) Log-normal (1.23; 0.10) PAMI41,42 y otros22,25,43
DD 777.06 (621.65-1087.88) Log-normal (6.65; 0.15) PAMI41,42
ICU hospitalization 3279.50 (2623.60-3935.40) Log-normal (8.09; 0.10) PAMI41,42
Others
Discount rate (%) 5 (0-10) - Mercosur guidelines27
Cohort (N) 1000 - - Assumption
CE threshold ($) 210 212 - - World Bank 201529; ER 201749
CE indicates cost-effectiveness; CRRT, continuous renal replacement therapy; DD, dialysis dependence; DI, dialysis independence; ER, exchange
rate; ICU, intensive unit care; IRRT, intermittent renal replacement therapy; PAMI, National Institute of Social Services for Retirees and Pen-
sioners; RRT, renal replacement therapy.
* Same estimates for CTRR and IRRT.
y See methods for details on range estimations.
z Probability distribution parameters were derived from the corresponding variability ranges.
x Average official exchange rate for 2016 was 14.78 (Banco Central de la República Argentina).
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experts panel, which resulted in a similar value of the one re-
ported by Zarbock et al in 2016.34We adapted the original model to
be able to switch from IRRT to CRRT, for which the experts panel
agreed to be 35.0% (95% CI: 13-43).
Evidence suggests that initiation with CRRT or IRRT has no
implication for long-term patient survival.13,16,17,19,35e39 Thus, we
assumed no differences in survival between cohorts. This was the
same strategy followed by Ethgen et al.25 We projected survival
until day 180 and then obtained a long-term curve using risk es-
timates from the cohort of De Corte 201630 and Schiffl 2012,31 that
were followed for a longer period (7 and 10 years, respectively).
Further methodological details on this projection can be found in
the Appendix in Supplemental Materials found at https://doi.org/1
0.1016/j.vhri.2019.03.008. Regarding the chronic DD associated
with the type of therapy received in ICU, we used the meta-
analyzed estimation of Schneider et al 201318 from the group of
randomized controlled trials of “satisfactory” quality according to
the Jaddad scale: 0.68 (0.38-1.22). Utility estimates for ICU stay, DD,
and dialysis independence (DI) were estimated by the panel of
experts using vignettes for different health states and the EuroQol
EQ-5D-3L questionnaire. Experts were required to complete them
as if they were patients. The EQ-5D-3L health states were then
valued using Argentinean social weights.40 Local utility values
were estimated as follows: ICU stay0.34 (0.38 to0.18), dialysis
unit 0.63 (0.46-0.77), and DI 0.81 (0.65-0.90). See the Appendix inSupplemental Materials found at https://doi.org/10.1016/j.vhri.201
9.03.008 for more details.Cost Parameters
The model requires estimations of daily local costs per patient of
IRRT and CRRT at ICU, and costs per day of DI and DD patients,
after discharge. All values are reported in local currency (AR$) of
2016 value. The daily cost of IRRT according to PAMI’s public
registries is $1952.92.41,42 Because we did not find costs estima-
tions in Argentina for CRRT, we calculated them based on the cost
ratio of CRRT/IRRT observed in international evidence. Three
studied were found to be relevant for this exercise, as they re-
ported both costs of CRRT and IRRT.22,25,43 The average ratio was
calculated in 3.6:1 (CRRT 3.6 times IRRT), with aminimum value of
3.2:122 and a maximum of 3.8:1.25 These ratios were then evalu-
ated by the local experts, which in the process of reaching
consensus estimated a cost ratio in 4:1 (3.2-5.6). The cost of CRRT
was finally estimated bymultiplying this ratio with the daily costs
of IRRT, which in turn resulted in $7811.68 ($6249.34-$10 936.35).
To estimate DD daily costs, we assumed DD to be the treatment of
chronic kidney disease with hemodialysis, which is reported by
PAMI to cost $1793.22 per session.41,42 Considering that it is ex-
pected that a patient performs 13 hemodialysis sessions per
month, the daily cost was calculated as follows: $1793.22 13/30¼
$777.06.44e46 The DI costs include medical consultation with
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serum creatinine, ionogram, and calcemia, among others. The
expected resource utilization was estimated from Kidney Disease
Improving Global Outcomes Clinical Guidelines for Acute Renal
Failure,15 and were valued using publicly accessible PAMI unit
costs.41,42 The daily cost for DI state was estimated at $5.53.41,42
Sensitivity Analyses
To study the impact of uncertainty on results, we have run several
sensitivity analyses (SAs). We used a deterministic SA (DSA) to
illustrate the impact of 1-way variations on the base-case NMB
(see ranges used in Table 1). Results in this case were summarized
in a tornado diagram to visualize which parameters had the
greatest individual influence on results. For the probabilistic SA
(PSA), CE results were simulated 1000 times to calculate proba-
bilities of CRRT being CE (P[CE]), to graph a scatterplot over the CE
plane and to derive a cost-effectiveness acceptability curve. The
PSA results were also used to perform a threshold analysis and
build a CE price threshold curve to show how changing the costs of
both therapies would affect the P(CE). Assumptions of probability
distributions and its parameters can be found in Table 1. We
additionally analyzed how the following scenarios changed the
base-case results: (1) with a lifetime horizon, (2) higher ICU days
for CRRT patients, (3) less RRT sessions for CRRT patients, (4)
considering the base-case risk ratio (RR) of CRRT/IRRT of Wald
201413 instead of the RRmeta-analyzed from the RCT of Schneider
et al,18 and (5) considering the global RR of DDmeta-analyzed from
Schneider et al18 instead of the RRmeta-analyzed from the RCT. A
detailed explanation of each scenario is in the Appendix in Sup-
plemental Materials found at https://doi.org/10.1016/j.vhri.2019.
03.008.Results
Cost Utility Results
Table 2 shows both discounted and undiscounted base-case re-
sults. In both cases, CRRT dominated IRRT by showing moreTable 2 – Results from case base. Accumulated costs per person
effectiveness. PAMI, Argentina, 2016.
IRRT CRRT D
Without discount
Total costs $123 681 $110 561
RRT cost $10 611 $25311
Hospitalizations costs $25 989 $25989
DI costs $1444 $1567
DD costs $111 625 $83683
QALYs 1.232 1.249
Results of CE - -
With discount (5%)
Total costs $103 871 $95362
RRT cost $10 611 $25311
Hospitalizations costs $25 989 $25989
ID costs $1205 $1308
DD costs $92 055 $68743
QALYs 1.034 1.049
Results of CE - -
Note. Average official exchange rate for 2016 was 14.78 (Banco Central de
CE indicates cost-effective; CRRT, continuous renal replace therapy; DD
cost-effectiveness ratio; IRRT, intermittent renal replacement therapy; N
for Retirees and Pensioners; P(CE), probability of CRRT being CE; RRT, renQALYs and less costs in the cumulative count. The discounted
QALYs for the cohorts were 1049 in CRRT and 1034 in IRRT, and the
total costs were $95362 and $103 871, respectively. The CE results
reflect these differences in favor of CRRT with a negative incre-
mental CE ratio. TheNMB resulted in $11623 and the P(CE) of CRRT
considering a CE threshold of 1 GDP per capita for Argentina was
65.4%. Undiscounted results were similar to discounted ones.
Continuous RRT compared with IRRT gained more QALYs (1249 vs
1233) with less total costs ($110 561 vs $123 681). As in the dis-
counted scenario, CRRT dominated IRRT. The NMB was estimated
at $16 851 and the probability of CRRT being CE lightly increases to
68.5%.Sensitivity Analyses Results
Deterministic SA results are summarized in Figure 2, in which the
main parameters were ranked according to its force to change the
discounted base-case NMB. If the NMB turns negative in DSA, it
means CRRT is not CE. This analysis shows that for 2 cases, if the
inferior limits were considered instead of their central or base-
case values, the resulting NMB would have been negative, mak-
ing CRRT not CE compared to IRRT. These parameters were 90-day
RR for dialysis dependence and the RRT duration in the ICU. All
other parameters’ uncertainty showed to be less important in this
sense, with no ability to change CE results individually.
The PSA in Figure 3 and Appendix Figure A1 in Supplemental
Materials found at https://doi.org/10.1016/j.vhri.2019.03.008
resume the PSA. Figure 3 is a scatterplot of 1000 simulated re-
sults over the CE plane. The bigger central dot represents the
deterministic result, while the smaller points scattered
throughout the plane show the possible results, taking into ac-
count the assumed variability of each of the parameters
(assumed probability distributions, see Table 1). The green line
crossing the northeast quadrant represents the CE threshold. All
points below this line are CE simulations of CRRT. In total, 65.4%
of the simulated results were CE for CRRT. Appendix Figure A1 in
Supplemental Materials found at https://doi.org/10.1016/j.vhri.2
019.03.008 is the acceptability curve of CRRT according to
different CE thresholds. The probability of CRRT being CE($ARS), QALYs accumulated per person, and results of cost-
ifference ICER NMB P(CE)
$13 120 - - -
$14 700 - - -
$0 - - -
$123 - - -
$27 942 - - -
0.018 - - -
- CRRT dominates $16 851 68.5%
$8510 - - -
$14 700 - - -
$0 - - -
$103 - - -
$23 312
0.015 - - -
- CRRT dominates $11 623 65.4%
la República Argentina).
, dialysis dependence; DI, dialysis independence; ICER, incremental
MB, net monetary benefit; PAMI, National Institute of Social Services
al replacement therapy; QALYs, quality-adjusted life years.
Figure 2 – Base case tornado graph. A positive net monetary benefit indicates that CRRT is cost-effective compared with IRRT
for the CE threshold considered in the study (1 GDPPc). IRRT indicates intermittent renal replacement therapy; CRRT,
continuous renal replacement therapy; DI, dialysis independence; DD, dialysis dependence; GDPpc, gross domestic product
per capita.
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peculiar form of the curve responds to the characteristics of the
uncertainty observed in the scatter plot, where a large number of
simulations fall in the fourth or northwest quadrant (less effec-
tive and more costly).
The threshold analysis in Figure 4 shows how the probability of
CRRT being CE changes for different RRT costs. Because the un-
certainty associated with RR is very influential, the variations in
the costs of RRT have a slight impact on CRRT probabilities of
being CE, and therefore great changes are needed in the costs of
RRT to affect the P(CE).Figure 3 – Probabilistic sensitivity analysis (PSA). 1,000
simulated results. The cost-effectiveness threshold is 1
GDPpc. The difference in costs and QALYs are expressed
per individual. IRRT indicates intermittent renal
replacement therapy; CRRT, continuous renal replacement
therapy; DI, dialysis independence; DD, dialysis
dependence; QALY, quality adjusted life year; CE, cost-
effectiveness; GDPpc, gross domestic product per capita.The Appendix summarizes results of each of the scenario an-
alysesmentioned before (see Appendix in Supplemental Materials
found at https://doi.org/10.1016/j.vhri.2019.03.008). In all cases,
CRRT’s probability of being cost-effective exceeded 50% when
considering a CE threshold of 1 GDP per capita. In general, results
were similar to those of the base case. In scenario 5, where an RR
of DD at 90 days for CRRT compared with significant IRRT meta-
analyzed by Schneider 201318 was considered, the probability of
CRRT being CE was 94.8%.Discussion
This study objective was to analyze the cost utility of CRRT versus
IRRT for the perspective of PAMI, the insurance for the elderly in
Argentina.We estimated lifetime health outcomes and total direct
costs using a state transition model populated with parameters
obtained from the literature. A panel of local experts validated the
parameters used with a Delphi-like method. Our results suggest
that CRRTwould probably be cost-effective compared to IRRT. The
model showed CRRT dominating IRRT by cumulating more QALYs
and less costs for the discounted scenario (1049 vs 1034 and
$95362 vs $103 871) and the undiscounted one (1249 vs 1233 and
$110 561 vs $123 681). This result arises primarily as a consequence
of the higher probability of patients receiving IRRT being depen-
dent on dialysis at 90 days after receiving RRT, compared with
those receiving CRRT. However, uncertainty around this estimate,
the most important parameter according to the DSA, is notably
high. The tornado diagram suggests that the uncertainty around
the main 2 parameters were so high that could change the main
conclusions. These parameters are the duration of RRT that was
obtained from the consensus of experts and the RR of DD at 90
days from ICU.
The PSA incorporated the uncertainty of all the parameters
at the same time. From Figure 3, it is possible to obtain the
probability of CRRT being CE compared with IRRT when
considering a threshold of CE of 1 GDP per capita. This value
was estimated at 65.4%. That is, considering the uncertainty of
all the parameters of the model, CRRT is more likely to be CE
Figure 4 – Cost-effectiveness price thresholds. Probability of CRRT being cost-effective for different costs of CRRT and IRRT in
AR$. IRRT indicates intermittent renal replacement therapy; CRRT, continuous renal replacement therapy; DI, dialysis
independence; DD, dialysis dependence; PCE (CRRT), probability that CRRT is cost-effective compared with IRRT.
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that exists over the main parameters of the model, which leads
to the cloud of Figure 3 resulting in a large number of points in
the fourth quadrant, the CRRT acceptability curve increases as
the threshold of CE increases but does not exceed 80%
probability.
The CE threshold price curve (Fig 4) also responded to the
uncertainty that exists over the main parameters of the study.
The central point, reflecting current costs, lay below the line
dividing the preference for both therapies (where the probability
of being CE equals 50% for both therapies), that is, in the pref-
erence zone of CRRT. The analysis suggests that if CRRT prices
increase beyond a threshold of approximately $10 000, the pref-
erence according to the probability of being CE would change in
favor of IRRT.
These results are in line with those previously reported by
Ethgen et al25 for the United States and are against what was re-
ported in 2 economic evaluations also mentioned in their study:
Klarenbach et al47 and De Smedt et al.48
This analysis has a series of limitations that should make the
reader be cautious about results. Of main importance are the
uncertainty associated to the main model parameters, ex-post
highlighted by the tornado analysis, specially the 90-day RR of
DD and the lack of cost information for CRRT in Argentina. To
address them, we aimed to construct as many SAs as we
considered relevant for decision makers, and also we aimed to
validate the missing information with local experts using Delphi-
like panel methods. We believe of special interest are the CE
threshold curves regarding the prices of the technologies, from
which the probabilities of CRRT being CE can be deduced for a
wide range of CRRT and IRRT costs. Another limitation is
regarding the definition of the study perspective. The only pa-
rameters coming from sources of PAMI are unit costs. All clinical
estimates were obtained from non-local studies. As we could not
get better information sources to define PAMI’s perspective, the
Delphi panel was planned to overcome this issue. During the
consensus exercise, local experts validated the main assump-
tions made for PAMI.Conclusion
Results suggest that the CRRT strategy in patients with acute AKI,
eligible for CRRT or IRRT, is slightly less costly andmore beneficial
(ie, cost-saving) from the perspective of the national health in-
surance for the elderly (PAMI) in Argentina, with a probability of
being CE of 65.4%. We used the best information to which we had
access at the moment, which was in turn validated by local ex-
perts. However, there is considerable uncertainty around our re-
sults, mainly due to the lack of adequate controlled studies and
the lack of local data on the prognosis of these patients in
Argentina.
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